Gordian Biotechnology is introducing a method of screening hundreds of gene therapies simultaneously in an individual animal model - its co-founders explain

blonca9
Apr 25, 2024
1 min read

Francisco LePort and Martin Borch Jensen describe unpublished results unveiled today regarding the science behind the mosaic screening process that Gordian is using as a discovery platform focusing on aging related diseases.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Gordian Biotechnology is introducing a method of screening hundreds of gene therapies simultaneously in an individual animal model - its co-founders explain

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight